At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 31 enrolled
Drug / intervention
Zilucoplandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants With Generalized Myasthenia Gravis
In Brief
A Phase 3 clinical trial evaluating Zilucoplan for Generalized Myasthenia Gravis. Completed, enrolled 31 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Myasthenia Gravis
CountriesPoland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedJun 2024
Enrollment StartAug 2024
Primary CompletionJan 2025
Study CompletionFeb 2025
TodayJul 2026
First PostedJun 24, 2024
Enrollment StartAug 27, 2024
Primary CompletionJan 28, 2025
Study CompletionFeb 3, 2025
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.0 years ago
Interventions
Zilucoplandrug
Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.